BMRN
BIOMARIN PHARMACEUTICAL INC
Next earnings Aug 3, 2026 (after close) · consensus $0.73 EPS, $952M rev
Last earnings +2.6% on 2026-05-04
$58.99
▲ +2.29%$58.99▲ +6.92%
over 1Y
L $49.67H $64.08
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.3%
1W+2.9%
1M+10.6%
3M+6.3%
YTD-0.8%
1Y+6.9%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 34 analysts
Buy
Rare-disease biotech with 13% revenue growth led by Voxzogo and a pristine balance sheet, now levering up for the $4.8B Amicus deal.
Revenue $3.22B · FY2025
The read
The fundamentals carry the rating, but the price is rich (~77% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
BioMarin is a leading global rare-disease biotech with eight commercial therapies and a track record of turning genetic science into category-defining medicines. FY2025 revenue grew 12.9% to $3.22B, driven per the MD&A by ongoing expansion of VOXZOGO (achondroplasia) alongside a stable base of enzyme therapies (Vimizim, Naglazyme, Palynziq, Aldurazyme, Brineura). These are orphan drugs with durable pricing and limited competition, giving the top line unusual visibility for a biotech.
The FY2025 earnings dip is a function of investment, not deterioration. Net income fell 18.3% to $349M and EPS to $1.80 as R&D rose 23.4% to $922M and SG&A grew to support the VOXZOGO launch — choices that build the pipeline rather than signs of a failing business. Underlying cash generation is strong: operating cash flow jumped 44.5% to $828M, cash grew 39.1% to $1.31B, and the balance sheet is exceptionally clean at 0.25x liabilities/equity. Revenue has compounded steadily from $1.85B in FY2021 to $3.22B in FY2025.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:48 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Gross profit | — | — | — | — | — |
| Operating income | -$82.3M | $161M | $186M | $484M | $409M |
| Net income | -$64.1M | $142M | $168M | $427M | $349M |
| Diluted EPS | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Net margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.1B
EV / EBITDA20.6
EV / Sales3.1
EV / FCF13.9
P / FCF15.7
PEG (trailing)—
Earnings yield3.1%
FCF yield6.4%
Quality & risk
ROIC (est.)5.3%
Free cash flow$725M
Total debt—
Net cash$1.31B
Altman Z-Score5.67 safe
Piotroski F-Score4/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+0.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗8-KPeriod ending 2026-06-022026-06-04open ↗4Period ending 2026-05-202026-05-21open ↗4Period ending 2026-05-072026-05-11open ↗
Frequently asked
- Is BIOMARIN PHARMACEUTICAL INC (BMRN) a buy?
- BMRN currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Rare-disease biotech with 13% revenue growth led by Voxzogo and a pristine balance sheet, now levering up for the $4.8B Amicus deal.
- What is BMRN's fair value?
- A Modified-Graham model based on BMRN's SEC fundamentals estimates a fair value of about $13.77. It is an estimate from reported earnings, not a price target.
- Is BMRN overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, BMRN currently appears overvalued relative to its SEC-grounded earnings power.
- What is BIOMARIN PHARMACEUTICAL INC's quality score?
- BMRN scores 65.38445003499896/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001048477, latest 10-Q filed 2026-05-05) · EODHD · Proprietary analysis · as of 6/21/2026, 8:48:40 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.